Clareo Health | A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients
A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of COPD and post-bronchodilator FEV1 ≥ 50% of the predicted normal value and post-bronchodilator FEV1/FVC \< 0.7 (COPD Grade 1 or 2 by severity of airflow limitation (GOLD 2015)
Patients with CAT score ≥ 10 at Visit 0 and Visit 1.
Patients who are on and have been on tiotropium monotherapy for the past 3 months.
0 or 1 COPD exacerbation in the previous 12 months (not leading to hospital admission).
You may not be if
Treatment with any inhaled corticosteroid (ICS) in the 3 months prior to Visit 1.
COPD exacerbation between Visit 0 and 1.
Patients with concomitant pulmonary disease
Patients with a history of respiratory infection within 4 weeks prior to Visit 0.
Prior or current diagnosis of asthma.
Presence of any contraindication, warning, precaution, hypersensitivity to LABA and LAMA
